Ocugen doses first patient in Phase 3 OCU410 trial

Ocugen said the first patient was dosed in the global Phase 3 registrational trial of OCU410 for geographic atrophy. It also said the DMC recommended completing 8-month follow-up in the OCU410ST interim review.